Recent Press Releases

Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan

Reiterates Commitment to Consummating the Combination of Teva and Mylan JERUSALEM--(BUSINESS WIRE)--Apr. 22, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) today announced that it...

Big Data and Genomics Meet the Cloud: the First Unified Global Platform for Precision Medicine

SHANGHAI; CAMBRIDGE, Mass.; and MOUNTAIN VIEW, Calif., April 22, 2015 – WuXi PharmaTech (Cayman) Inc. ($WX), whose leading open-access R&D capability and technology platform serves the...

Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48

First Quarter 2015 GAAP EPS Were $2.11

THOUSAND OAKS, Calif., April 21, 2015 /PRNewswire/ -- Amgen (

Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan

This is an announcement falling under Rule 2.4 of Irish Takeover Panel Act, 1997, Takeover Rules, 2013 (the "Irish Takeover Rules"). Proposal Substantially Undervalues Perrigo and is...

Teva Proposes to Acquire Mylan for $82.00 Per Share in Cash and Stock

Combination to Create an Industry-Leading Company, Well Positioned to Transform the Global Generics Space and Create a Unique and Differentiated Business Model, Leveraging on Its Significant Assets...

Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis

INDIANAPOLIS, April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the inves

Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015

Diverse pipeline compounds target key cancer pathways

INDIANAPOLIS, April 20, 2015 /PRNewswire/ --&n

Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

Pembrolizumab Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer

Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman

Biogen CEO George A. Scangos and Johnson & Johnson Worldwide Chairman for Pharmaceuticals Joaquin Duato Assume New Posts ; Castellani Announces Retirement Washington, D.C. (April 16, 2015)...


NEW YORK (April 17, 2015) – Pfizer today released the following statement regarding the jury verdict in favor of the Company in the Pesante case, the first case to go to trial in Trace Foster...

Mylan Comments on Recent Media Speculation

POTTERS BAR, England, April 17, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today commented on recent media speculation. Mylan Executive Chairman Robert J. Coury commented, "We note that there...

Actavis Announces FDA Approval of Expanded Label for BOTOX(R) (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

Label updates include addition of two thumb flexor muscles and increased maximum cumulative dose DUBLIN, April 20, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), which recently completed the...

"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC

GENEVA, April 17, 2015 /PRNewswire/ --

CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated Non-Squamous Non-Small Cell Lung Cancer Friday, April 17, 2015 RINCETON, N.J.--Bristol-Myers...

Annual General Meeting Approves Dividend Increase

Executive Board actions approved by a significant majority Darmstadt, Germany, April 17, 2015 – At the Annual General Meeting of Merck held in Frankfurt am Main today, shareholders approved...

Merck Proposes Dividend Increase to AGM After a Year of Key Strategic Moves – Foundation Set for Further Organic Growth

Major highlights of 2014 include offer for Sigma-Aldrich, alliance with Pfizer and integration of AZ Electronic Materials  Merck proposes a dividend increase of € 0.05 to € 1.00 Darmstadt,...

Amgen Announces Webcast Of 2015 First Quarter Financial Results

THOUSAND OAKS, Calif., April 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will